Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer

Clinical Chemistry

Volumn 50, Issue 6, 2004, Pages 1017-1025

  Mikolajczyk, Stephen D ^a   Catalona, William J ^b   Evans, Cindy L ^a   Linton, Harry J ^a   Millar, Lisa S ^a   Marker, Kathy M ^a   Katir, Diksha ^a   Amirkhan, Anna ^a   Rittenhouse, Harry G ^a  

^a BECKMAN COULTER INC   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSS REACTION; DIAGNOSTIC ACCURACY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; ROC CURVE; SENSITIVITY AND SPECIFICITY;

AGED; AREA UNDER CURVE; ENZYME PRECURSORS; HUMANS; IMMUNOASSAY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 2642583188     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.026823     Document Type: Article

References (32)

1. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
2. Oesterling JE. Prostate-specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23.
3. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992;147:846-51.
4. Tchetgen MB, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am 1997;24:283-91.
5. 1-antichymotrypsin. Clin Chem 1991;37:1618-25.
6. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-6.
7. Zhang WM, Finne P, Leinonen J, Stenman UH. Characterization and determination of the complex between prostate-specific antigen and α 1-protease inhibitor in benign and malignant prostatic diseases. Scand J Clin Lab Invest Suppl 2000;51-8.
8. Miller MC, O'Dowd GJ, Partin AW, Veltri RW. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics. Urology 2001;57:1105-11.
9. Okihara K, Fritsche HA, Ayala A, Johnston DA, Allard WJ, Babaian RJ. Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng/ml. J Urol 2001;165:1930-6.
10. Mast AE, Enghild JJ, Pizzo SV, Salvesen G. Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of α-proteinase inhibitor, α1-antichymotrypsin, antithrombin III, α2-antiplasmin, angiotensinogen, and ovalbumin. Biochemistry 1991;30:1723-30.
11. Stenman UH, Leinonen J, Zhang WM, Finne P. Prostate-specific antigen. Semin Cancer Biol 1999;9:83-93.
12. Stephan C, Jung K, Brux B, Lein M, Sinha P, Schnorr D, et al. ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: proof of new complex forming of PSA after release into circulation. Urology 2000;55:560-3.
13. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-7.
14. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998;159:5-12.
15. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1983;52:655-709.
16. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol 1978;15:340-5.
17. Chen Z, Chen H, Stamey TA. Prostate specific antigen in benign prostatic hyperplasia: purification and characterization. J Urol 1997;157:2166-70.
18. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Marks LS, Song W, et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 2000;60:756-9.
19. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Wolfert RL, Marks LS, et al. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000;55:41-5.
20. Jung K, Brux B, Lein M, Rudolph B, Kristiansen G, Hauptmann S, et al. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications. Clin Chem 2000;46:47-54.
21. Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG. Free prostate-specific antigen in serum is becoming more complex. Urology 2002;59:797-802.
22. Khan AR, James MNG. Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci 1998;7:815-36.
23. Peter J, Unverzagt C, Krogh TN, Vorm O, Hoesel W. Identification of precursor forms of prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 2001;61:957-62.
24. Mikolajczyk SD, Marker KM, Millar LS, Kumar A, Saedi MS, Payne JK, et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001;61:6958-63.
25. Chan TY, Mikolajczyk SD, Lecksell K, Shue MJ, Rittenhouse HG, Partin AW, et al. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology 2003;62:177-81.
26. Sokoll LJ, Chan DW, Mikolajczyk SD, Rittenhouse HG, Evans CL, Linton HJ, et al. Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/ml total PSA range: preliminary analysis. Urology 2003;61:274-6.
27. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Amirkhan A, et al. Serum proPSA improves cancer detection compared to free and complexed PSA in men with PSA values from 2 to 4 ng/ml. J Urol 2003;170:2181-5.
28. Khan MA, Partin AW, Rittenhouse HG, Mikolajczyk SD, Sokoll LJ, Chan DW, et al. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol 2003;170:723-6.
29. Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997;57:3111-4.
30. Bunting PS, DeBoer G, Choo R, Danjoux C, Klotz L, Fleshner N. Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation. Clin Biochem 2002;35:471-5.
31. Finlay JA, Day JR, Evans CL, Carlson R, Kuus-Reichel K, Millar LS, et al. Development of a dual monoclonal antibody immunoassay for total human kallikrein 2. Clin Chem 2001;47:1218-24.
32. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Horninger W, et al. Serum pro-PSA preferentially detects aggressive prostate cancers in men with 2-4 ng/ml prostate specific antigen. J Urol 2004; in press.